Gene-Sequencing Company Illumina to Sell Cancer Test Developer
Illumina, the leading producer of gene-sequencing machines, announced Sunday that it would sell Grail, a cancer test developer that it purchased for $7.1 billion in 2021.The move came two days after Illumina lost its case in a federal appeals court, which largely upheld a Federal Trade Commission ruling that Illumina should unwind its deal with Grail on antitrust grounds.The case was seen by antitrust experts as a test of regulators’ efforts to stop big companies from buying fledgling innovators.The deal had also faced a roadblock in Europe. In September 2022, the European Union said it would block the acquisition. Illumina,…




